Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Equivalence point

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Equivalence point. Displaying page 2 of 2.
    « Previous 1  2 
    EudraCT Number: 2018-002930-19 Sponsor Protocol Number: XBR1001 Start Date*: 2019-02-25
    Sponsor Name:Xbrane Biopharma
    Full Title: A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane versus Lucentis® in Patients with Neovascular Age-Related Macular Degeneration
    Medical condition: Wet Age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) HU (Completed) SK (Completed) LV (Completed) CZ (Completed) BG (Completed) PL (Completed) ES (Ongoing) RO (Completed)
    Trial results: View results
    EudraCT Number: 2007-003853-97 Sponsor Protocol Number: PNB1 Start Date*: 2007-10-18
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: A 23-month randomised, masked, prospective phase IV study assessing the safety and efficacy of two alternative treatment regimes using Bevacizumab (AvastinTM) to treat patients with subfoveal and j...
    Medical condition: "wet" or "exudative" age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001970-41 Sponsor Protocol Number: 0504-19 Start Date*: 2022-03-18
    Sponsor Name:Intas Pharmaceuticals Ltd.
    Full Title: A Double Masked, Parallel Group, Randomized, Multicenter, Clinical Study to Compare Efficacy and Safety of Intas Ranibizumab with Lucentis® in Patients with Neovascular (Wet) Age-Related Macular De...
    Medical condition: Neovascular (Wet) Age-Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    27.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) PL (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006253-29 Sponsor Protocol Number: CLI00070 Start Date*: 2012-07-31
    Sponsor Name:Cerus Corporation
    Full Title: A Randomized Controlled Double-Blind Phase 3 Study to Assess Characteristics of S-303 Treated RBC Components and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia
    Medical condition: Acute anemia secondary to cardiovascular surgery.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10054312 Anemia postoperative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000160-34 Sponsor Protocol Number: BECRO/OV/BRIMTIM Start Date*: 2015-06-29
    Sponsor Name:OmniVision GmbH
    Full Title: Therapeutic Equivalence (non-inferiority), Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a new Generic Formulation of 0.2% Brimonidin...
    Medical condition: Open angle glaucoma or ocular hypertension.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    18.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    18.0 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005540-34 Sponsor Protocol Number: CLR_14_12 Start Date*: 2016-07-19
    Sponsor Name:Sun Pharma Advanced Research Company, Ltd. (SPARC)
    Full Title: A Multi-Center, Investigator-Masked, Randomized, Crossover, Equivalence Study of the Safety and Efficacy of Once Daily Brimonidine Tartrate 0.35% Ophthalmic Suspension Compared with Brimonidine Tar...
    Medical condition: Open-angle glaucoma, chronic angle closure glaucoma with patent iridotomy, pseudoexfoliation, pigment dispersion, or ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    19.1 10015919 - Eye disorders 10018304 Glaucoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-002875-25 Sponsor Protocol Number: NEO-CIRC-003 Start Date*: 2018-07-24
    Sponsor Name:SERMAS-FIBHULP
    Full Title: An international multicentre randomized placebo-controlled, double blind three arm trial to investigate the efficacy of dobutamine with two different starting doses in the treatment of haemodynamic...
    Medical condition: Haemodynamic insufficiency (Haemodynamic insufficiency after birth is commonly seen in babies born prematurely. The condition has a significant clinical impact. A final common pathway is seen but ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10009196 Circulatory failure neonatal PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003971-12 Sponsor Protocol Number: MK-1293-003 Start Date*: 2014-04-01
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus? in Subjects With Type 1 Diabetes Mellitus.
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    16.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-006545-36 Sponsor Protocol Number: B1000-PMO-03-G-02 Start Date*: 2022-05-18
    Sponsor Name:Biocon Biologics UK Limited
    Full Title: A Randomized, Double-blind, Multicenter, Parallel-arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia in Postmenopausal Women with O...
    Medical condition: Postmenopausal women diagnosed with osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: EE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016720-31 Sponsor Protocol Number: 250901 Start Date*: 2010-06-09
    Sponsor Name:Baxter Innovations GmbH [...]
    1. Baxter Innovations GmbH
    2. Baxter Healthcare Corporation
    Full Title: BAX 326 (recombinant Factor IX): A Phase 1/3 Prospective, Controlled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, Immunogenicity in Previously Treated Patients with Severe (FIX...
    Medical condition: Previously treated patients with severe (FIX level < 1%) or moderately severe (FIX level ≤ 2%) hemophilia B.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) ES (Completed) BG (Completed) SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 12 11:03:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA